Published in Eur J Pharmacol on July 01, 1976
Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis. J Clin Invest (1988) 0.89
Thromboxane-insensitive dog platelets have impaired activation of phospholipase C due to receptor-linked G protein dysfunction. J Clin Invest (1993) 0.86
Platelet-leukocyte interactions following arterial endothelial injury. Am J Pathol (1979) 0.84
Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo. J Clin Invest (1986) 0.82
The roles of prostaglandin endoperoxides, thromboxane A2 and adenosine diphosphate in collagen-induced aggregation in man and the rat. Br J Pharmacol (1986) 0.82
The effect of oral phenylbutazone on whole blood platelet aggregation in the dog. Can J Comp Med (1985) 0.81
Biotransformation of arachidonic acid in the circulation of the dog [proceedings]. Br J Pharmacol (1978) 0.75
Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. Eur J Pharmacol (1980) 2.90
The role of platelet-activating factor in platelet aggregation. Nature (1979) 2.37
Background and present status of research on platelet-activating factor (PAF-acether). Ann N Y Acad Sci (1981) 2.22
Critical role of cytosolic phospholipase A2{alpha} in bronchial mucus hypersecretion in CFTR-deficient mice. Eur Respir J (2010) 1.51
Systemic administration of endotoxin induces bronchopulmonary hyperreactivity dissociated from TNF-alpha formation and neutrophil sequestration into the murine lungs. J Immunol (1998) 1.33
Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat. Effects of three platelet-activating factor antagonists. Gastroenterology (1987) 1.24
Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988. Eur J Pharmacol (1986) 1.17
Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils. J Leukoc Biol (1997) 1.17
Inhibition by sulfhydryl agents of arachidonic acid-induced platelet aggregation and release of potential inflammatory substances. Prostaglandins (1974) 1.16
Present concepts on the mechanisms of platelet aggregation. Biochem Pharmacol (1981) 1.15
Cathepsin G is a strong platelet agonist released by neutrophils. Biochem J (1988) 1.14
Platelet-activating factor (PAF-acether) secretion from platelets: effect of aggregating agents. Br J Haematol (1980) 1.12
Effect of cyclo-oxygenase inhibitors and modulators of cyclic AMP formation on lipopolysaccharide-induced neutrophil infiltration in mouse lung. Br J Pharmacol (1996) 1.10
A critical evaluation of three methods for the study of adrenergic beta-blocking and anti-arrhythmic agents. Eur J Pharmacol (1969) 1.05
Direct evidence for the existence of a neutrophil-derived platelet activator (neutrophilin). Proc Natl Acad Sci U S A (1986) 1.05
Non-steroidal anti-inflammatory drugs if combined with anti-histamine and anti-serotonin agents interfere with the bronchial and platelet effects of "platelet-activating factor" (PAF-acether). Eur J Pharmacol (1982) 1.02
Biosynthesis of platelet-activating factor (PAF-ACETHER). II. Involvement of phospholipase A2 in the formation of PAF-ACETHER and lyso-PAF-ACETHER from rabbit platelets. Thromb Res (1982) 1.02
Proteolysis of monocyte CD14 by human leukocyte elastase inhibits lipopolysaccharide-mediated cell activation. J Clin Invest (1999) 0.99
Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-acether) in the guinea pig. Eur J Pharmacol (1982) 0.95
Lack of IL-10 synthesis by murine alveolar macrophages upon lipopolysaccharide exposure. Comparison with peritoneal macrophages. J Leukoc Biol (2000) 0.95
Activation of human platelets by C5a-stimulated neutrophils: a role for cathepsin G. Am J Physiol (1990) 0.93
Release of platelet-activating factor (PAF-acether) and 2-lyso PAF-acether from three cell types. Agents Actions (1982) 0.90
Blockade by metal complexing agents and by catalase of the effects of arachidonic acid on platelets: relevance to the study of anti-inflammatory mechanisms. Eur J Pharmacol (1975) 0.89
A noel type of substituted piperazine with high antiserotonin potency. J Med Chem (1970) 0.89
Innate immunity and inflammation--two facets of the same anti-infectious reaction. Clin Exp Immunol (2009) 0.88
Enhancement of cathepsin G-induced platelet activation by leukocyte elastase: consequence for the neutrophil-mediated platelet activation. Blood (1993) 0.88
Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung. Br J Pharmacol (1998) 0.88
Activation of guinea-pig platelets induced by convulxin, a substance extracted from the venom of Crotalus durissus cascavella. Eur J Pharmacol (1980) 0.88
Tumor necrosis factor-alpha enhances platelet activation via cathepsin G released from neutrophils. J Immunol (1991) 0.88
[Platelet aggregation and platelet activating factor (author's transl)]. J Pharmacol (1981) 0.87
Role of the metabolites of arachidonate in platelet-dependent and independent experimental bronchoconstriction. Bull Eur Physiopathol Respir (1981) 0.86
Effects of PAF-acether and structural analogues on platelet activation and bronchoconstriction in guinea-pigs. Eur J Pharmacol (1986) 0.85
Proteinase 3. A neutrophil proteinase with activity on platelets. J Immunol (1994) 0.85
Convulxin-induced activation of intact and of thrombin-degranulated rabbit platelets: specific crossed desensitisation with collagen. Eur J Pharmacol (1983) 0.85
Dissociation of platelet activation from transmethylation of their membrane phospholipids. Nature (1981) 0.85
Heparin inhibits neutrophil-induced platelet activation via cathepsin G. J Lab Clin Med (1992) 0.85
Human neutrophil cathepsin G down-regulates LPS-mediated monocyte activation through CD14 proteolysis. J Leukoc Biol (2000) 0.84
Interference of recombinant eglin C, a proteinase inhibitor extracted from leeches, with neutrophil-mediated platelet activation. Lab Invest (1990) 0.84
Cooperation between platelets and neutrophils for paf-acether (platelet-activating factor) formation. J Leukoc Biol (1990) 0.84
Platelet-lung in vivo interactions: an artifact of a multi-purpose model? Haemostasis (1979) 0.84
Combined activation of platelets by cathepsin G and platelet activating factor, two neutrophil-derived agonists. Br J Haematol (1992) 0.84
Inhibition by recombinant SLPI and half-SLPI (Asn55-Ala107) of elastase and cathepsin G activities: consequence for neutrophil-platelet cooperation. Br J Pharmacol (1993) 0.83
One, two, three or more pathways for platelet aggregation. Acta Med Scand Suppl (1980) 0.83
Inhibition of neutrophil serine proteinases by suramin. J Biol Chem (1997) 0.83
Proteolysis of thrombospondin during cathepsin-G-induced platelet aggregation: functional role of the 165-kDa carboxy-terminal fragment. FEBS Lett (1996) 0.82
[Effect of non-narcotic analgesics on hypotension due to bradykinin]. Experientia (1966) 0.82
Platelet-tissue interaction: role of platelet-activating factor (PAF-acether). Agents Actions (1980) 0.82
Azithromycin analogue CSY0073 attenuates lung inflammation induced by LPS challenge. Br J Pharmacol (2014) 0.82
Down-regulation by prostaglandins of type-II phospholipase A2 expression in guinea-pig alveolar macrophages: a possible involvement of cAMP. Biochem J (1998) 0.82
Extended freeze-dried Mycobacterium bovis Bacillus Calmette-Guérin induces the release of interleukin-12 but not tumour necrosis factor-alpha by alveolar macrophages, both in vitro and in vivo. Clin Exp Allergy (2003) 0.81
Constitutional thrombocytopathy with subnormal response to thromboxane A2. Br J Haematol (1981) 0.81
Substances that increase the cyclic AMP content prevent platelet aggregation and the concurrent release of pharmacologically active substances evoked by arachidonic acid. Agents Actions (1975) 0.81
Surfactant protein A suppresses lipopolysaccharide-induced IL-10 production by murine macrophages. J Immunol (2001) 0.81
Activation and damage of cultured airway epithelial cells by human elastase and cathepsin G. Eur J Pharmacol (1992) 0.80
L8027 and 1-nonyl-imidazole as non-selective inhibitors of thromboxane synthesis. Eur J Pharmacol (1979) 0.80
Paf-acether formation and arachidonic acid freeing from platelet ether-linked glyceryl-phosphorylcholine. Biochem Biophys Res Commun (1984) 0.80
Secretome of human bronchial epithelial cells in response to the fungal pathogen Aspergillus fumigatus analyzed by differential in-gel electrophoresis. J Infect Dis (2012) 0.79
Neutrophil proteinase cathepsin G is proteolytically active on the human platelet glycoprotein Ib-IX receptor: characterization of the cleavage sites within the glycoprotein Ib alpha subunit. Biochem J (1994) 0.79
A role for PAF-acether (platelet-activating factor) in platelet-dependent vascular diseases? Circulation (1985) 0.79
Leukocytic functions in burn-injured patients. Prostaglandins (1985) 0.78
Interference of bromophenacyl bromide with platelet phospholipase A2 activity induced by thrombin and by the ionophore A23187. Thromb Res (1980) 0.78
Inhibition by ticlopidine of Paf-acether-induced in vitro aggregation of rabbit and human platelets. Thromb Res (1984) 0.78
The phospholipase C/protein kinase C pathway is involved in cathepsin G-induced human platelet activation: comparison with thrombin. Biochem J (1996) 0.78
Role of paf-acether and related ether-lipid metabolism in platelets. Adv Exp Med Biol (1985) 0.77
3 Deazaadenosine and L-homocysteine inhibit platelet aggregation induced by collagen and convulxin through a phospholipase A2 independent mechanism. Thromb Res (1982) 0.76
Synthesis of thromboxane A2 by non-aggregating dog platelets challenged with arachidonic acid or with prostaglandin H2. Prostaglandins (1977) 0.76
Neutrophil serine proteases are most probably involved in the release of CD43 (leukosialin, sialophorin) from the neutrophil membrane during cell activation. Blood (1996) 0.76
Use of steroidal antiinflammatory drug provides further evidence for a potential role of PAF-acether in bronchial anaphylaxis. Int Arch Allergy Appl Immunol (1986) 0.76
Interference of transmethylation inhibitors with thromboxane synthesis in rat platelets. Biochem Biophys Res Commun (1982) 0.76
Transient activation of the acetyltransferase necessary for paf-acether biosynthesis in thrombin-activated platelets. Br J Haematol (1986) 0.76
Regulation of the structure and activity of platelet adhesion receptors by leukocyte proteinases. Nouv Rev Fr Hematol (1994) 0.76
Interference of anti-inflammatory and anti-asthmatic drugs with neutrophil-mediated platelet activation: singularity of azelastine. Br J Pharmacol (1991) 0.76
Protective effect of platelet activating factor antagonists on cultured endothelial cell lysis induced by elastase or activated neutrophils. Br J Pharmacol (1996) 0.75
Familial and constitutional bleeding disorder due to platelet cyclo-oxygenase deficiency. Am J Hematol (1983) 0.75
Exercise- and allergen-induced asthma do not change the production of Paf-acether by neutrophils and platelets. Bull Eur Physiopathol Respir (1988) 0.75
Synergism between interleukin-8 and tumor necrosis factor-alpha for neutrophil-mediated platelet activation. Eur Cytokine Netw (1995) 0.75
[Effects of some nonsteroid anti-inflammatory agents on the hypotensive action of bradykinin]. Therapie (1971) 0.75
Pharmacological properties of PAF-acether in the guinea-pig: platelet-dependent and independent reactions. Agents Actions (1982) 0.75
New vistas on the role of platelets in bronchoconstrictions. Agents Actions Suppl (1979) 0.75
Modulation by superoxide anions of neutrophil-mediated platelet activation. Biochem Pharmacol (1994) 0.75
Progressive inactivation of cathepsin G and elastase released from activated neutrophils in vitro: lack of participation of the neutrophil alpha 1-proteinase inhibitor. J Lab Clin Med (1994) 0.75
Possible participation of adenosine 5'-diphosphate, arachidonic acid and paf-acether in the platelet pro-aggregating effect of uncontrolled insulin-dependent diabetic erythrocytes in vitro. Thromb Res (1985) 0.75
Inhibition by human leukocyte elastase of neutrophil-mediated platelet activation. Eur J Pharmacol (1993) 0.75
Methylation inhibitors impair collagen-induced activation of human platelets. Thromb Haemost (1983) 0.75
Inhibition of neutrophil-endothelial cell adhension by a neutrophil product, cathepsin G. J Leukoc Biol (1996) 0.75
Synthesis of thromboxane B2 in incubates of dog platelet-rich plasma with arachidonic acid and its inhibition by different drugs. Biochem Biophys Res Commun (1978) 0.75
Dissociation between inhibition of phospholipid methylation and production of PAF-acether by rabbit platelets. Experientia (1984) 0.75
Comparative pharmacology of arachidonic acid in various animal species: platelet-mediated and platelet-indipendent reactions [proceedings]. Agents Actions (1978) 0.75
Inhibitory effects of three new synthetic compounds on human platelet aggregation. Thromb Res (1986) 0.75
Platelet activation induced by FMLP-stimulated neutrophils. Agents Actions Suppl (1986) 0.75
Interference of transmethylation inhibitors with thromboxane synthesis in rat platelets: evidence for the requirement of a methyl transfer reaction in platelet activation. Adv Prostaglandin Thromboxane Leukot Res (1983) 0.75
Why do some beta adrenergic agonists inhibit generation of thromboxane A2 in incubates of platelets with arachidonic acid? Biochem Pharmacol (1978) 0.75
Neutrophil-mediated platelet activation: a key role for serine proteinases. Gen Pharmacol (1995) 0.75
Carrageenan-induced activation of human platelets is independent of phospholipase A2 and of formation of thromboxanes. J Pharm Pharmacol (1980) 0.75
Eglin C and heparin inhibition of platelet activation induced by cathepsin G or human neutrophils. Ann N Y Acad Sci (1991) 0.75
Arachidonate-mediated bronchoconstriction and platelet activation are inhibited by microgram doses of compound L8027 which are not selective for thromboxane synthetase. Agents Actions Suppl (1979) 0.75